This commentary discusses the unmet clinical and social needs associated with hypertrophic scars and keloids. The authors critically appraise these issues within the context of contemporary clinical standards of care and social mores catalyzed by the COVID-19 pandemic.
Keywords: dermatology; drug development; hypertrophic scars; keloids; regenerative medicine.